期刊文献+

低温干燥过程中LEA蛋白对胰岛素结构稳定性的研究 被引量:2

Investigation on Bioactive Protection of LEA Protein for Insulin by Molecular Simulation in the Low-temperature Drying Process
原文传递
导出
摘要 当前蛋白药物日益在许多疾病的诊断、预防和治疗方面表现出重要的作用。然而,蛋白药物具有热敏性的特点,其活性结构大多不够稳定。因此,研究热敏性蛋白药物的有效保护方法并探究其保护机制对热敏蛋白药物的生产、贮存和应用具有重大的研究意义和实用价值。本文选择胰岛素为热敏性蛋白药物,胚胎发育晚期丰富(LEA)蛋白为活性保护剂,通过分子模拟方法详细研究了LEA蛋白对胰岛素生物活性的保护作用。研究结果表明:与没有任何保护的胰岛素的活性三维结构相比,LEA蛋白对胰岛素活性三维结构具有良好的保护作用,而且受保护的胰岛素的二级结构也非常稳定。由此可见,LEA蛋白是一个优良的热敏蛋白药物活性保护剂。 Nowadays various protein medicines are increasingly playing significant roles in the treatment of many diseases,but the bioactive structures of such kinds of protein medicines are unstable because they are heat sensitive.Therefore,it is very important to explore a protective method and to explain the protective mechanism of protein medicines.In the present research,insulin was chosen as a heat-sensitive protein medicine,and a Group 3 late embryogenesis abundant(LEA) protein was chosen as its bioactive protectant during desiccation.The results of replica exchange molecular dynamics simulation suggest that comparing with insulin without any protection,the bioactive 3D structure and secondary structure of the insulin protected by LEA protein were preserved very well.All analyzing results proved that the LEA protein was a good bioactive protectant for heat sensitive protein medicines.
出处 《生物医学工程学杂志》 EI CAS CSCD 北大核心 2013年第4期854-859,共6页 Journal of Biomedical Engineering
基金 国家自然科学基金资助项目(51076108) 上海市科技创新行动计划国际科技合作项目(12430702000) 上海市重点学科项目资助(T0503 P0502) 上海市自然科学基金资助项目(12ZR1420400) 上海市联盟计划项目
关键词 胰岛素 胚胎发育晚期丰富蛋白 生物活性保护 分子模拟 Insulin Late embryogenesis abundant(LEA) protein Bioactivity protection Molecular simulation
  • 相关文献

参考文献32

  • 1BRANGE J, LANGKJOER L. Insulin structure and stability [J]. Pharm Biotechnol, 1993, 5: 315-350.
  • 2HUI X, CHEN H, ZHANG S, et al. Antitumor activities of recombinant human interferon (IFN)-λ1 in vitro and in xeno- graft models in vivo for colon cancer[J]. Cancer Lett, 2011, 311(2) : 141-151.
  • 3GERSHANOVICH M L, FILATOVA L V, KETLINSKY S A, et al. Recombinant human interleukin-1 beta: new possi bilities for the prophylaxis and correction of toxic myelode- pression in patients with malignant tumors. Ⅱ Phase Ⅱ study of the protective effect of recombinant human interleukin-1 beta on myelodepression induced by chemotherapy in cancer patients[J]. Eur Cytokine Netw, 2001, 12(4) :671-675.
  • 4GERSHANOVICH M L, FILATOVA L V, KETIANSKY S A, et al. Recombinant human interleukin-1 beta: new possi- bilities for the prophylaxis and correction of toxic myelode- pression in patients with malignant tumors. I Phase I-II clinical trials of recombinant human interleukin-1 beta as a leukopoiesis stimulator in cancer patients receiving combina- tion chemotherapy[J]. Eur Cytokine Netw, 2001, 12 (4) : 664-670.
  • 5STEPHENNE J. Production in yeast versus mammalian cells of the first recombinant DNA human vaccine and its proved safety, efficacy, and economy: hepatitis B vaccine[J]. Adv Biotechnol Processes, 1990, 14 : 279-299.
  • 6ABDUL-FATTAH A M, TRUONG-LE V, YEE L, et al. Drying-induced variations in physico-ehemical properties of a- morphous pharmaceuticals and their impact on stability( I ) : stability of a monoclonal antibody[J]. J Pharm Sci, 2007, 96 (8) : 1983-2008.
  • 7ABDUL-FATTAH A M, TRUONG-LE V, YEE L, et al. Drying-induced variations in physico-chemical properties of a- morphous pharmaceuticals and their impact on stability II : stability of a vaccine[J]. Pharm Res, 2007, 24(4) : 715-727.
  • 8SALVUCCI M E, OSTERYOUNG K W, CRAFTS-BRAND- NER S J, et al. Exceptional sensitivity of rubisco activase to thermal denaturation in vitro and in vivo [J]. Plant Physiol, 2001, 127(3): 1053-1064.
  • 9GILLES G J, HINES K M, MANFRE A J, et al. A predic- ted N-terminal helical domain of a Group 1 LEA protein is re- quired for protection of enzyme activity from drying[J]. Plant Physiol Biochem, 2007, 45(6-7):389-399.
  • 10TOROSANTUCCI R, KUKRER B, MERO A, et al. Plain and mono-pegylated recombinant human insulin exhibit similar stress-induced aggregation profiles[J]. J Pharm Sci, 2011, 100(7) :2574-2585.

二级参考文献3

共引文献8

同被引文献10

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部